{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:51:33Z","timestamp":1788558693477,"version":"build-2803163510"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dutch Arthritis Association","award":["11-1-306"],"award-info":[{"award-number":["11-1-306"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s12016-015-8522-7","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T08:21:39Z","timestamp":1449130899000},"page":"27-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside\u2014a Comprehensive Review"],"prefix":"10.1007","volume":"51","author":[{"given":"C. Henrique","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar M.","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lubberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"issue":"5","key":"8522_CR1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401\u2013419","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"8522_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/ar2502","volume":"10","author":"IE Adamopoulos","year":"2008","unstructured":"Adamopoulos IE, Bowman EP (2008) Immune regulation of bone loss by Th17 cells. Arthritis Res Ther 10(5):225","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"8522_CR3","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1073\/pnas.87.12.4828","volume":"87","author":"W Wiktor-Jedrzejczak","year":"1990","unstructured":"Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, Ahmed-Ansari A, Sell KW, Pollard JW, Stanley ER (1990) Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op\/op) mouse. Proc Natl Acad Sci U S A 87(12):4828\u20134832","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"8522_CR4","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A 95(7):3597\u20133602","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8522_CR5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm.3432","volume":"20","author":"N Komatsu","year":"2014","unstructured":"Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20(1):62\u201368","journal-title":"Nat Med"},{"issue":"1","key":"8522_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.imlet.2011.02.022","volume":"138","author":"S Kamiya","year":"2011","unstructured":"Kamiya S, Okumura M, Chiba Y, Fukawa T, Nakamura C, Nimura N, Mizuguchi J, Wada S, Yoshimoto T (2011) IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett 138(1):47\u201353","journal-title":"Immunol Lett"},{"issue":"7","key":"8522_CR7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1359\/jbmr.2000.15.7.1321","volume":"15","author":"M Kanematsu","year":"2000","unstructured":"Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y (2000) Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand\/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 15(7):1321\u20131329","journal-title":"J Bone Miner Res"},{"issue":"10","key":"8522_CR8","doi-asserted-by":"crossref","first-page":"e1004497","DOI":"10.1371\/journal.ppat.1004497","volume":"10","author":"K Titanji","year":"2014","unstructured":"Titanji K, Vunnava A, Sheth AN, Delille C, Lennox JL, Sanford SE, Foster A, Knezevic A, Easley KA, Weitzmann MN et al (2014) Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog 10(10):e1004497","journal-title":"PLoS Pathog"},{"key":"8522_CR9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","volume":"20","author":"LE Theill","year":"2002","unstructured":"Theill LE, Boyle WJ, Penninger JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795\u2013823","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"8522_CR10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF01995720","volume":"73","author":"A Weichselbaum","year":"1878","unstructured":"Weichselbaum A (1878) Die feineren ver\u00e4nderungen des gelenkknorpels bei fung\u00f6ser synovitis und karies der gelenkenden. Arch Pathol Anat Physiol Klin Med 73(4):461\u2013475","journal-title":"Arch Pathol Anat Physiol Klin Med"},{"issue":"9","key":"8522_CR11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/art.1780270902","volume":"27","author":"M Bromley","year":"1984","unstructured":"Bromley M, Woolley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 27(9):968\u2013975","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8522_CR12","first-page":"17","volume":"15","author":"JC Leisen","year":"1988","unstructured":"Leisen JC, Duncan H, Riddle JM, Pitchford WC (1988) The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. J Rheumatol 15(1):17\u201322","journal-title":"J Rheumatol"},{"issue":"4","key":"8522_CR13","first-page":"943","volume":"152","author":"EM Gravallese","year":"1998","unstructured":"Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152(4):943\u2013951","journal-title":"Am J Pathol"},{"issue":"12","key":"8522_CR14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/ard.61.12.1047","volume":"61","author":"TN Crotti","year":"2002","unstructured":"Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR (2002) Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61(12):1047\u20131054","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8522_CR15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00296-011-1831-0","volume":"32","author":"AS Ellabban","year":"2012","unstructured":"Ellabban AS, Kamel SR, Ahmed SS, Osman AM (2012) Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Rheumatol Int 32(6):1589\u20131596","journal-title":"Rheumatol Int"},{"issue":"6759","key":"8522_CR16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","volume":"402","author":"YY Kong","year":"1999","unstructured":"Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759):304\u2013309","journal-title":"Nature"},{"issue":"11","key":"8522_CR17","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.38114","volume":"65","author":"C Engdahl","year":"2013","unstructured":"Engdahl C, Lindholm C, Stubelius A, Ohlsson C, Carlsten H, Lagerquist MK (2013) Periarticular bone loss in antigen-induced arthritis. Arthritis Rheum 65(11):2857\u20132865","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8522_CR18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","volume":"161","author":"E Romas","year":"2002","unstructured":"Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT (2002) Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161(4):1419\u20131427","journal-title":"Am J Pathol"},{"issue":"11","key":"8522_CR19","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1002\/art.10607","volume":"46","author":"E Lubberts","year":"2002","unstructured":"Lubberts E, Oppers-Walgreen B, Pettit AR, Van Den Bersselaar L, Joosten LA, Goldring SR, Gravallese EM, Van Den Berg WB (2002) Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 46(11):3055\u20133064","journal-title":"Arthritis Rheum"},{"issue":"7","key":"8522_CR20","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.20382","volume":"50","author":"NA Sims","year":"2004","unstructured":"Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E (2004) Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 50(7):2338\u20132346","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8522_CR21","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","volume":"159","author":"AR Pettit","year":"2001","unstructured":"Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM (2001) TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159(5):1689\u20131699","journal-title":"Am J Pathol"},{"issue":"11","key":"8522_CR22","doi-asserted-by":"crossref","first-page":"e15383","DOI":"10.1371\/journal.pone.0015383","volume":"5","author":"C Yang","year":"2010","unstructured":"Yang C, McCoy K, Davis JL, Schmidt-Supprian M, Sasaki Y, Faccio R, Novack DV (2010) NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis. PLoS One 5(11):e15383","journal-title":"PLoS One"},{"issue":"1","key":"8522_CR23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/annrheumdis-2012-202832","volume":"73","author":"B Orosa","year":"2014","unstructured":"Orosa B, Garcia S, Martinez P, Gonzalez A, Gomez-Reino JJ, Conde C (2014) Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. Ann Rheum Dis 73(1):298\u2013305","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"8522_CR24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI0215582","volume":"110","author":"K Redlich","year":"2002","unstructured":"Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110(10):1419\u20131427","journal-title":"J Clin Invest"},{"issue":"3","key":"8522_CR25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.10097","volume":"46","author":"K Redlich","year":"2002","unstructured":"Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S et al (2002) Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46(3):785\u2013792","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8522_CR26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.37797","volume":"65","author":"NB Binder","year":"2013","unstructured":"Binder NB, Puchner A, Niederreiter B, Hayer S, Leiss H, Bluml S, Kreindl R, Smolen JS, Redlich K (2013) Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum 65(3):608\u2013617","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8522_CR27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0092-8674(00)80258-5","volume":"89","author":"T Komori","year":"1997","unstructured":"Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M et al (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89(5):755\u2013764","journal-title":"Cell"},{"issue":"1","key":"8522_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","volume":"108","author":"K Nakashima","year":"2002","unstructured":"Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108(1):17\u201329","journal-title":"Cell"},{"issue":"1","key":"8522_CR29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.0105-2896.2009.00857.x","volume":"233","author":"NC Walsh","year":"2010","unstructured":"Walsh NC, Gravallese EM (2010) Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233(1):301\u2013312","journal-title":"Immunol Rev"},{"issue":"1","key":"8522_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11914-013-0183-y","volume":"12","author":"R Baum","year":"2014","unstructured":"Baum R, Gravallese EM (2014) Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep 12(1):9\u201316","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"8522_CR31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.37762","volume":"65","author":"D Balani","year":"2013","unstructured":"Balani D, Aeberli D, Hofstetter W, Seitz M (2013) Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. Arthritis Rheum 65(2):436\u2013446","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8522_CR32","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1210\/endo.141.12.7840","volume":"141","author":"F Gori","year":"2000","unstructured":"Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141(12):4768\u20134776","journal-title":"Endocrinology"},{"issue":"3","key":"8522_CR33","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","volume":"139","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M et al (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139(3):1329\u20131337","journal-title":"Endocrinology"},{"issue":"11","key":"8522_CR34","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.3654","volume":"20","author":"S Moverare-Skrtic","year":"2014","unstructured":"Moverare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Borjesson AE, Sjogren K, Windahl SH, Farman H, Kindlund B et al (2014) Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. Nat Med 20(11):1279\u20131288","journal-title":"Nat Med"},{"issue":"9","key":"8522_CR35","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","volume":"142","author":"YL Ma","year":"2001","unstructured":"Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142(9):4047\u20134054","journal-title":"Endocrinology"},{"issue":"4","key":"8522_CR36","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/en.2004-1167","volume":"146","author":"XH Liu","year":"2005","unstructured":"Liu XH, Kirschenbaum A, Yao S, Levine AC (2005) Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin\/receptor activator of nuclear factor-{kappa}B (RANK) ligand\/RANK system. Endocrinology 146(4):1991\u20131998","journal-title":"Endocrinology"},{"issue":"6","key":"8522_CR37","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/cdd.2014.8","volume":"21","author":"MR Byun","year":"2014","unstructured":"Byun MR, Hwang JH, Kim AR, Kim KM, Hwang ES, Yaffe MB, Hong JH (2014) Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation. Cell Death Differ 21(6):854\u2013863","journal-title":"Cell Death Differ"},{"issue":"Pt 7","key":"8522_CR38","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","volume":"119","author":"GJ Spencer","year":"2006","unstructured":"Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG (2006) Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119(Pt 7):1283\u20131296","journal-title":"J Cell Sci"},{"issue":"8B","key":"8522_CR39","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1582-4934.2008.00569.x","volume":"13","author":"N Tang","year":"2009","unstructured":"Tang N, Song WX, Luo J, Luo X, Chen J, Sharff KA, Bi Y, He BC, Huang JY, Zhu GH et al (2009) BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt\/beta-catenin signalling. J Cell Mol Med 13(8B):2448\u20132464","journal-title":"J Cell Mol Med"},{"issue":"5","key":"8522_CR40","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar430","volume":"4","author":"DJ Shealy","year":"2002","unstructured":"Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, Wagner CL, Mayton L, Griswold DE, Song XY (2002) Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 4(5):R7","journal-title":"Arthritis Res"},{"issue":"5","key":"8522_CR41","first-page":"581","volume":"22","author":"N Maruotti","year":"2007","unstructured":"Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D (2007) Macrophages in rheumatoid arthritis. Histol Histopathol 22(5):581\u2013586","journal-title":"Histol Histopathol"},{"issue":"5","key":"8522_CR42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/ar113","volume":"2","author":"T Pap","year":"2000","unstructured":"Pap T, Muller-Ladner U, Gay RE, Gay S (2000) Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2(5):361\u2013367","journal-title":"Arthritis Res"},{"issue":"9","key":"8522_CR43","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1359\/jbmr.090320","volume":"24","author":"NC Walsh","year":"2009","unstructured":"Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24(9):1572\u20131585","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8522_CR44","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.33504","volume":"64","author":"MM Matzelle","year":"2012","unstructured":"Matzelle MM, Gallant MA, Condon KW, Walsh NC, Manning CA, Stein GS, Lian JB, Burr DB, Gravallese EM (2012) Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum 64(5):1540\u20131550","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8522_CR45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156\u2013163","journal-title":"Nat Med"},{"issue":"5","key":"8522_CR46","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3899\/jrheum.100089","volume":"38","author":"SY Wang","year":"2011","unstructured":"Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, Li ZG (2011) Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 38(5):821\u2013827","journal-title":"J Rheumatol"},{"issue":"3","key":"8522_CR47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00223-004-0285-8","volume":"77","author":"A Brandao-Burch","year":"2005","unstructured":"Brandao-Burch A, Utting JC, Orriss IR, Arnett TR (2005) Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int 77(3):167\u2013174","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"8522_CR48","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.yexcr.2006.02.007","volume":"312","author":"JC Utting","year":"2006","unstructured":"Utting JC, Robins SP, Brandao-Burch A, Orriss IR, Behar J, Arnett TR (2006) Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 312(10):1693\u20131702","journal-title":"Exp Cell Res"},{"issue":"3","key":"8522_CR49","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar1943","volume":"8","author":"H Ideguchi","year":"2006","unstructured":"Ideguchi H, Ohno S, Hattori H, Senuma A, Ishigatsubo Y (2006) Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther 8(3):R76","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"8522_CR50","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1003370","volume":"186","author":"B Pollinger","year":"2011","unstructured":"Pollinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, Bay S, Keller R, Raulf F, Di Padova F et al (2011) Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol 186(4):2602\u20132612","journal-title":"J Immunol"},{"issue":"12","key":"8522_CR51","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106(12):1481\u20131488","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"8522_CR52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/oxfordjournals.rheumatology.a031490","volume":"39","author":"DL Scott","year":"2000","unstructured":"Scott DL (2000) Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 39(Suppl 1):24\u201329","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"8522_CR53","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1084\/jem.146.3.857","volume":"146","author":"DE Trentham","year":"1977","unstructured":"Trentham DE, Townes AS, Kang AH (1977) Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 146(3):857\u2013868","journal-title":"J Exp Med"},{"issue":"Suppl 3","key":"8522_CR54","first-page":"S51","volume":"7","author":"R Holmdahl","year":"1989","unstructured":"Holmdahl R, Mo J, Nordling C, Larsson P, Jansson L, Goldschmidt T, Andersson M, Klareskog L (1989) Collagen induced arthritis: an experimental model for rheumatoid arthritis with involvement of both DTH and immune complex mediated mechanisms. Clin Exp Rheumatol 7(Suppl 3):S51\u201355","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"8522_CR55","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/art.1780281213","volume":"28","author":"RE Esser","year":"1985","unstructured":"Esser RE, Stimpson SA, Cromartie WJ, Schwab JH (1985) Reactivation of streptococcal cell wall-induced arthritis by homologous and heterologous cell wall polymers. Arthritis Rheum 28(12):1402\u20131411","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8522_CR56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/art.23152","volume":"58","author":"LA Joosten","year":"2008","unstructured":"Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, Helsen MM, van den Bersselaar LA, Oppers-Walgreen B, Koenders MI, van den Berg WB (2008) T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum 58(1):98\u2013108","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8522_CR57","first-page":"520","volume":"57","author":"JW Lens","year":"1984","unstructured":"Lens JW, van den Berg WB, van de Putte LB, Berden JH, Lems SP (1984) Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: effects of pre-treatment with cobra venom factor and anti-lymphocyte serum. Clin Exp Immunol 57(3):520\u2013528","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"8522_CR58","doi-asserted-by":"crossref","first-page":"e57553","DOI":"10.1371\/journal.pone.0057553","volume":"8","author":"F Cornelissen","year":"2013","unstructured":"Cornelissen F, Asmawidjaja PS, Mus AM, Corneth O, Kikly K, Lubberts E (2013) IL-23 dependent and independent stages of experimental arthritis: no clinical effect of therapeutic IL-23p19 inhibition in collagen-induced arthritis. PLoS One 8(2):e57553","journal-title":"PLoS One"},{"issue":"1","key":"8522_CR59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0002-9440(10)62961-6","volume":"167","author":"MI Koenders","year":"2005","unstructured":"Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, Boots AM, Gram H, Joosten LA, van den Berg WB (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167(1):141\u2013149","journal-title":"Am J Pathol"},{"issue":"5445","key":"8522_CR60","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1126\/science.286.5445.1732","volume":"286","author":"I Matsumoto","year":"1999","unstructured":"Matsumoto I, Staub A, Benoist C, Mathis D (1999) Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286(5445):1732\u20131735","journal-title":"Science"},{"issue":"6965","key":"8522_CR61","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nature02119","volume":"426","author":"N Sakaguchi","year":"2003","unstructured":"Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S et al (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426(6965):454\u2013460","journal-title":"Nature"},{"issue":"6","key":"8522_CR62","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20052187","volume":"203","author":"S Sawa","year":"2006","unstructured":"Sawa S, Kamimura D, Jin GH, Morikawa H, Kamon H, Nishihara M, Ishihara K, Murakami M, Hirano T (2006) Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3\/IL-7-dependent homeostatic proliferation of CD4+ T cells. J Exp Med 203(6):1459\u20131470","journal-title":"J Exp Med"},{"issue":"2","key":"8522_CR63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.191.2.313","volume":"191","author":"R Horai","year":"2000","unstructured":"Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y (2000) Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191(2):313\u2013320","journal-title":"J Exp Med"},{"issue":"13","key":"8522_CR64","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","volume":"10","author":"J Keffer","year":"1991","unstructured":"Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10(13):4025\u20134031","journal-title":"EMBO J"},{"issue":"4","key":"8522_CR65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s003359900998","volume":"10","author":"BA Taylor","year":"1999","unstructured":"Taylor BA, Wnek C, Kotlus BS, Roemer N, MacTaggart T, Phillips SJ (1999) Genotyping new BXD recombinant inbred mouse strains and comparison of BXD and consensus maps. Mamm Genome 10(4):335\u2013348","journal-title":"Mamm Genome"},{"issue":"2","key":"8522_CR66","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ni1552","volume":"9","author":"HC Hsu","year":"2008","unstructured":"Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL et al (2008) Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9(2):166\u2013175","journal-title":"Nat Immunol"},{"issue":"7114","key":"8522_CR67","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nature05245","volume":"443","author":"K Kawane","year":"2006","unstructured":"Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, Yoshikawa H, Nagata S (2006) Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 443(7114):998\u20131002","journal-title":"Nature"},{"issue":"1","key":"8522_CR68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0896-8411(18)30379-2","volume":"8","author":"E Buchner","year":"1995","unstructured":"Buchner E, Brauer R, Schmidt C, Emmrich F, Kinne RW (1995) Induction of flare-up reactions in rat antigen-induced arthritis. J Autoimmun 8(1):61\u201374","journal-title":"J Autoimmun"},{"issue":"7","key":"8522_CR69","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60(7):1895\u20131905","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8522_CR70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/eji.201141871","volume":"42","author":"K Zwerina","year":"2012","unstructured":"Zwerina K, Koenders M, Hueber A, Marijnissen RJ, Baum W, Heiland GR, Zaiss M, McLnnes I, Joosten L, van den Berg W et al (2012) Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol 42(2):413\u2013423","journal-title":"Eur J Immunol"},{"issue":"5748","key":"8522_CR71","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/283666a0","volume":"283","author":"JS Courtenay","year":"1980","unstructured":"Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B (1980) Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283(5748):666\u2013668","journal-title":"Nature"},{"issue":"1","key":"8522_CR72","first-page":"26","volume":"54","author":"ES Cathcart","year":"1986","unstructured":"Cathcart ES, Hayes KC, Gonnerman WA, Lazzari AA, Franzblau C (1986) Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen. Lab Investig 54(1):26\u201331","journal-title":"Lab Investig"},{"issue":"1","key":"8522_CR73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00441-009-0816-8","volume":"339","author":"KS Nandakumar","year":"2010","unstructured":"Nandakumar KS (2010) Pathogenic antibody recognition of cartilage. Cell Tissue Res 339(1):213\u2013220","journal-title":"Cell Tissue Res"},{"key":"8522_CR74","first-page":"214","volume":"26","author":"A Tarkowski","year":"1989","unstructured":"Tarkowski A, Holmdahl R, Klareskog L (1989) Rheumatoid factors in mice. Monogr Allergy 26:214\u2013229","journal-title":"Monogr Allergy"},{"issue":"2","key":"8522_CR75","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1084\/jem.180.2.517","volume":"180","author":"GH Nabozny","year":"1994","unstructured":"Nabozny GH, Bull MJ, Hanson J, Griffiths MM, Luthra HS, David CS (1994) Collagen-induced arthritis in T cell receptor V beta congenic B10.Q mice. J Exp Med 180(2):517\u2013524","journal-title":"J Exp Med"},{"issue":"6","key":"8522_CR76","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/1521-4141(200006)30:6<1568::AID-IMMU1568>3.0.CO;2-R","volume":"30","author":"IK Campbell","year":"2000","unstructured":"Campbell IK, Hamilton JA, Wicks IP (2000) Collagen-induced arthritis in C57BL\/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 30(6):1568\u20131575","journal-title":"Eur J Immunol"},{"issue":"7","key":"8522_CR77","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/annrheumdis-2012-202055","volume":"72","author":"J Backlund","year":"2013","unstructured":"Backlund J, Li C, Jansson E, Carlsen S, Merky P, Nandakumar KS, Haag S, Ytterberg J, Zubarev RA, Holmdahl R (2013) C57BL\/6 mice need MHC class II Aq to develop collagen-induced arthritis dependent on autoreactive T cells. Ann Rheum Dis 72(7):1225\u20131232","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8522_CR78","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00109-011-0841-4","volume":"90","author":"B Pollinger","year":"2012","unstructured":"Pollinger B (2012) IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis. J Mol Med (Berl) 90(6):613\u2013624","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"8522_CR79","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-3083.1985.tb01884.x","volume":"22","author":"R Holmdahl","year":"1985","unstructured":"Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H (1985) T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol 22(3):295\u2013306","journal-title":"Scand J Immunol"},{"issue":"3","key":"8522_CR80","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2567.2001.01257.x","volume":"103","author":"M Ehinger","year":"2001","unstructured":"Ehinger M, Vestberg M, Johansson AC, Johannesson M, Svensson A, Holmdahl R (2001) Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology 103(3):291\u2013300","journal-title":"Immunology"},{"issue":"3","key":"8522_CR81","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/art.1780200314","volume":"20","author":"D Brackertz","year":"1977","unstructured":"Brackertz D, Mitchell GF, Mackay IR (1977) Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 20(3):841\u2013850","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8522_CR82","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.146.6.1585","volume":"146","author":"WJ Cromartie","year":"1977","unstructured":"Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH (1977) Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 146(6):1585\u20131602","journal-title":"J Exp Med"},{"issue":"2","key":"8522_CR83","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2249.1990.tb05194.x","volume":"79","author":"MF Broek van den","year":"1990","unstructured":"van den Broek MF, van Bruggen MC, Stimpson SA, Severijnen AJ, van de Putte LB, van den Berg WB (1990) Flare-up reaction of streptococcal cell wall induced arthritis in Lewis and F344 rats: the role of T lymphocytes. Clin Exp Immunol 79(2):297\u2013306","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"8522_CR84","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4049\/jimmunol.151.8.4344","volume":"151","author":"JB Allen","year":"1993","unstructured":"Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM (1993) Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 151(8):4344\u20134351","journal-title":"J Immunol"},{"issue":"4","key":"8522_CR85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1074-7613(00)80045-X","volume":"10","author":"AS Korganow","year":"1999","unstructured":"Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL et al (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10(4):451\u2013461","journal-title":"Immunity"},{"issue":"11","key":"8522_CR86","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.4049\/jimmunol.169.11.6604","volume":"169","author":"M Corr","year":"2002","unstructured":"Corr M, Crain B (2002) The role of FcgammaR signaling in the K\/B x N serum transfer model of arthritis. J Immunol 169(11):6604\u20136609","journal-title":"J Immunol"},{"issue":"3","key":"8522_CR87","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1521-4141(200203)32:3<644::AID-IMMU644>3.0.CO;2-5","volume":"32","author":"S Solomon","year":"2002","unstructured":"Solomon S, Kolb C, Mohanty S, Jeisy-Walder E, Preyer R, Schollhorn V, Illges H (2002) Transmission of antibody-induced arthritis is independent of complement component 4 (C4) and the complement receptors 1 and 2 (CD21\/35). Eur J Immunol 32(3):644\u2013651","journal-title":"Eur J Immunol"},{"issue":"9","key":"8522_CR88","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1172\/JCI11530","volume":"107","author":"Y Niki","year":"2001","unstructured":"Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, Fujikawa K, Tada N (2001) Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest 107(9):1127\u20131135","journal-title":"J Clin Invest"},{"issue":"12","key":"8522_CR89","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344(12):907\u2013916","journal-title":"N Engl J Med"},{"issue":"4","key":"8522_CR90","first-page":"225","volume":"6","author":"DM Butler","year":"1995","unstructured":"Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6(4):225\u2013230","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"8522_CR91","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1074\/jbc.M008198200","volume":"276","author":"YH Zhang","year":"2001","unstructured":"Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y (2001) Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276(1):563\u2013568","journal-title":"J Biol Chem"},{"issue":"52","key":"8522_CR92","doi-asserted-by":"crossref","first-page":"49343","DOI":"10.1074\/jbc.M103642200","volume":"276","author":"SE Lee","year":"2001","unstructured":"Lee SE, Chung WJ, Kwak HB, Chung CH, Kwack KB, Lee ZH, Kim HH (2001) Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 276(52):49343\u201349349","journal-title":"J Biol Chem"},{"issue":"4","key":"8522_CR93","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/ard.2003.008458","volume":"63","author":"D O\u2019Gradaigh","year":"2004","unstructured":"O\u2019Gradaigh D, Ireland D, Bord S, Compston JE (2004) Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 63(4):354\u2013359","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"8522_CR94","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1172\/JCI26132","volume":"115","author":"H Kitaura","year":"2005","unstructured":"Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115(12):3418\u20133427","journal-title":"J Clin Invest"},{"issue":"10","key":"8522_CR95","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/art.23943","volume":"58","author":"S Herman","year":"2008","unstructured":"Herman S, Muller RB, Kronke G, Zwerina J, Redlich K, Hueber AJ, Gelse H, Neumann E, Muller-Ladner U, Schett G (2008) Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 58(10):3041\u20133050","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8522_CR96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1359\/JBMR.0301233","volume":"19","author":"P Li","year":"2004","unstructured":"Li P, Schwarz EM, O\u2019Keefe RJ, Ma L, Boyce BF, Xing L (2004) RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 19(2):207\u2013213","journal-title":"J Bone Miner Res"},{"issue":"20","key":"8522_CR97","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","volume":"89","author":"RO Williams","year":"1992","unstructured":"Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89(20):9784\u20139788","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"8522_CR98","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/14397595.2014.886351","volume":"24","author":"H Okazaki","year":"2014","unstructured":"Okazaki H, Lin Q, Nishikawa K, Ohtsuji N, Tsurui H, Ohtsuji M, Amano H, Tada N, Sudo K, Nishimura H et al (2014) TNFalpha but not IL-17 is critical in the pathogenesis of rheumatoid arthritis spontaneously occurring in a unique FcgammaRIIB-deficient mouse model. Mod Rheumatol 24(6):931\u2013938","journal-title":"Mod Rheumatol"},{"issue":"3 Suppl 59","key":"8522_CR99","first-page":"S5","volume":"28","author":"DE Furst","year":"2010","unstructured":"Furst DE (2010) Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 28(3 Suppl 59):S5\u201312","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"8522_CR100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/ar112","volume":"2","author":"C Ritchlin","year":"2000","unstructured":"Ritchlin C (2000) Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2(5):356\u2013360","journal-title":"Arthritis Res"},{"issue":"12","key":"8522_CR101","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.4049\/jimmunol.145.12.4181","volume":"145","author":"P Seckinger","year":"1990","unstructured":"Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG (1990) Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 145(12):4181\u20134184","journal-title":"J Immunol"},{"issue":"1","key":"8522_CR102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1084\/jem.164.1.104","volume":"164","author":"BM Thomson","year":"1986","unstructured":"Thomson BM, Saklatvala J, Chambers TJ (1986) Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. J Exp Med 164(1):104\u2013112","journal-title":"J Exp Med"},{"issue":"1","key":"8522_CR103","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/excr.1998.4320","volume":"247","author":"E Jimi","year":"1999","unstructured":"Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, Suda T (1999) Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts\/stromal cells. Exp Cell Res 247(1):84\u201393","journal-title":"Exp Cell Res"},{"issue":"2","key":"8522_CR104","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1210\/endo.136.2.7835314","volume":"136","author":"E Jimi","year":"1995","unstructured":"Jimi E, Shuto T, Koga T (1995) Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells. Endocrinology 136(2):808\u2013811","journal-title":"Endocrinology"},{"issue":"2","key":"8522_CR105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.191.2.275","volume":"191","author":"K Kobayashi","year":"2000","unstructured":"Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N et al (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction. J Exp Med 191(2):275\u2013286","journal-title":"J Exp Med"},{"issue":"3","key":"8522_CR106","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cyto.2004.02.001","volume":"26","author":"T Ma","year":"2004","unstructured":"Ma T, Miyanishi K, Suen A, Epstein NJ, Tomita T, Smith RL, Goodman SB (2004) Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha. Cytokine 26(3):138\u2013144","journal-title":"Cytokine"},{"issue":"1","key":"8522_CR107","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4049\/jimmunol.172.1.577","volume":"172","author":"Y Niki","year":"2004","unstructured":"Niki Y, Yamada H, Kikuchi T, Toyama Y, Matsumoto H, Fujikawa K, Tada N (2004) Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice. J Immunol 172(1):577\u2013584","journal-title":"J Immunol"},{"issue":"7","key":"8522_CR108","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.4049\/jimmunol.159.7.3604","volume":"159","author":"SC Ghivizzani","year":"1997","unstructured":"Ghivizzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, Watkins SC, Tindal MH, Suchanek MK, McKenzie LR et al (1997) Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 159(7):3604\u20133612","journal-title":"J Immunol"},{"issue":"1","key":"8522_CR109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1084\/jem.20020439","volume":"196","author":"H Ji","year":"2002","unstructured":"Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C (2002) Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196(1):77\u201385","journal-title":"J Exp Med"},{"issue":"1","key":"8522_CR110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.11487","volume":"50","author":"J Zwerina","year":"2004","unstructured":"Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J et al (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50(1):277\u2013290","journal-title":"Arthritis Rheum"},{"issue":"28","key":"8522_CR111","doi-asserted-by":"crossref","first-page":"11742","DOI":"10.1073\/pnas.0610812104","volume":"104","author":"J Zwerina","year":"2007","unstructured":"Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O et al (2007) TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 104(28):11742\u201311747","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8522_CR112","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.104786","volume":"69","author":"K Polzer","year":"2010","unstructured":"Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W et al (2010) Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 69(1):284\u2013290","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8522_CR113","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115(2):282\u2013290","journal-title":"J Clin Invest"},{"issue":"6","key":"8522_CR114","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964\u2013975","journal-title":"Ann Rheum Dis"},{"key":"8522_CR115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","volume":"34","author":"C Garbers","year":"2015","unstructured":"Garbers C, Aparicio-Siegmund S, Rose-John S (2015) The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol 34:75\u201382","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"8522_CR116","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/art.1780400614","volume":"40","author":"H Okamoto","year":"1997","unstructured":"Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z (1997) The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 40(6):1096\u20131105","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8522_CR117","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0090-1229(89)90146-3","volume":"50","author":"A Waage","year":"1989","unstructured":"Waage A, Kaufmann C, Espevik T, Husby G (1989) Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol 50(3):394\u2013398","journal-title":"Clin Immunol Immunopathol"},{"issue":"6","key":"8522_CR118","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","volume":"31","author":"FA Houssiau","year":"1988","unstructured":"Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31(6):784\u2013788","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8522_CR119","first-page":"22","volume":"19","author":"B Dasgupta","year":"1992","unstructured":"Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G (1992) Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19(1):22\u201325","journal-title":"J Rheumatol"},{"issue":"1","key":"8522_CR120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","volume":"11","author":"S Kotake","year":"1996","unstructured":"Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11(1):88\u201395","journal-title":"J Bone Miner Res"},{"issue":"11","key":"8522_CR121","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.4049\/jimmunol.144.11.4226","volume":"144","author":"N Kurihara","year":"1990","unstructured":"Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD (1990) IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 144(11):4226\u20134230","journal-title":"J Immunol"},{"issue":"24","key":"8522_CR122","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","volume":"90","author":"T Tamura","year":"1993","unstructured":"Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T et al (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 90(24):11924\u201311928","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"8522_CR123","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/art.24781","volume":"60","author":"R Axmann","year":"2009","unstructured":"Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60(9):2747\u20132756","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8522_CR124","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cyto.2008.05.007","volume":"43","author":"Y Li","year":"2008","unstructured":"Li Y, Backesjo CM, Haldosen LA, Lindgren U (2008) IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. Cytokine 43(2):165\u2013173","journal-title":"Cytokine"},{"issue":"11","key":"8522_CR125","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/art.22175","volume":"54","author":"F Benedetti De","year":"2006","unstructured":"De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P et al (2006) Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 54(11):3551\u20133563","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8522_CR126","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1006\/cyto.1999.0502","volume":"11","author":"A Boe","year":"1999","unstructured":"Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O (1999) Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11(12):1057\u20131064","journal-title":"Cytokine"},{"issue":"14","key":"8522_CR127","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1073\/pnas.95.14.8222","volume":"95","author":"S Ohshima","year":"1998","unstructured":"Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M et al (1998) Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 95(14):8222\u20138226","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8522_CR128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/art.21537","volume":"54","author":"PK Wong","year":"2006","unstructured":"Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54(1):158\u2013168","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8522_CR129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","volume":"187","author":"T Alonzi","year":"1998","unstructured":"Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, Ciliberto G (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187(4):461\u2013468","journal-title":"J Exp Med"},{"issue":"12","key":"8522_CR130","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P","volume":"41","author":"N Takagi","year":"1998","unstructured":"Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, Takeda Y, Ohsugi Y (1998) Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41(12):2117\u20132121","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8522_CR131","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/cei.12201","volume":"175","author":"K Tanaka","year":"2014","unstructured":"Tanaka K, Hashizume M, Mihara M, Yoshida H, Suzuki M, Matsumoto Y (2014) Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model. Clin Exp Immunol 175(2):172\u2013180","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"8522_CR132","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5(12):1731\u20131740","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"8522_CR133","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162\u20131167","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8522_CR134","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC (2014) Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 73(9):1626\u20131634","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8522_CR135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","volume":"17","author":"M Roy Van","year":"2015","unstructured":"Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, t Hart B, Poelmans S, Bontinck L et al (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther 17(1):135","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"8522_CR136","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B (2014) Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73(9):1616\u20131625","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"8522_CR137","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","volume":"71","author":"P Mease","year":"2012","unstructured":"Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J (2012) A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 71(7):1183\u20131189","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8522_CR138","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4161\/mabs.28612","volume":"6","author":"S Shaw","year":"2014","unstructured":"Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al (2014) Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs 6(3):774\u2013782","journal-title":"MAbs"},{"issue":"4","key":"8522_CR139","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jmb.2011.06.031","volume":"411","author":"DK Finch","year":"2011","unstructured":"Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S et al (2011) Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol 411(4):791\u2013807","journal-title":"J Mol Biol"},{"issue":"1","key":"8522_CR140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clim.2010.10.002","volume":"138","author":"G Zizzo","year":"2011","unstructured":"Zizzo G, De Santis M, Bosello SL, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clin Immunol 138(1):107\u2013116","journal-title":"Clin Immunol"},{"issue":"9","key":"8522_CR141","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103(9):1345\u20131352","journal-title":"J Clin Invest"},{"issue":"10","key":"8522_CR142","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrrheum.2015.128","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E (2015) The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11(10):562","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"8522_CR143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cyto.2015.02.002","volume":"74","author":"SM Paulissen","year":"2015","unstructured":"Paulissen SM, van Hamburg JP, Dankers W, Lubberts E (2015) The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine 74(1):43\u201353","journal-title":"Cytokine"},{"issue":"12","key":"8522_CR144","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1084\/jem.20071397","volume":"204","author":"K Hirota","year":"2007","unstructured":"Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T et al (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204(12):2803\u20132812","journal-title":"J Exp Med"},{"issue":"4","key":"8522_CR145","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jcb.22326","volume":"108","author":"T Yago","year":"2009","unstructured":"Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, Kotake S (2009) IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 108(4):947\u2013955","journal-title":"J Cell Biochem"},{"issue":"6","key":"8522_CR146","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","volume":"74","author":"IE Adamopoulos","year":"2015","unstructured":"Adamopoulos IE, Suzuki E, Chao CC, Gorman D, Adda S, Maverakis E, Zarbalis K, Geissler R, Asio A, Blumenschein WM et al (2015) IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Ann Rheum Dis 74(6):1284\u20131292","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8522_CR147","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.4049\/jimmunol.170.5.2655","volume":"170","author":"E Lubberts","year":"2003","unstructured":"Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand\/osteoprotegerin balance. J Immunol 170(5):2655\u20132662","journal-title":"J Immunol"},{"issue":"11","key":"8522_CR148","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","volume":"171","author":"S Nakae","year":"2003","unstructured":"Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171(11):6173\u20136177","journal-title":"J Immunol"},{"issue":"2","key":"8522_CR149","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","volume":"50","author":"E Lubberts","year":"2004","unstructured":"Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50(2):650\u2013659","journal-title":"Arthritis Rheum"},{"issue":"11","key":"8522_CR150","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3858\/emm.2012.44.11.078","volume":"44","author":"MJ Park","year":"2012","unstructured":"Park MJ, Park HS, Oh HJ, Lim JY, Yoon BY, Kim HY, Cho ML, Cho SG (2012) IL-17-deficient allogeneic bone marrow transplantation prevents the induction of collagen-induced arthritis in DBA\/1J mice. Exp Mol Med 44(11):694\u2013705","journal-title":"Exp Mol Med"},{"issue":"2","key":"8522_CR151","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.38229","volume":"66","author":"OB Corneth","year":"2014","unstructured":"Corneth OB, Mus AM, Asmawidjaja PS, Klein Wolterink RG, van Nimwegen M, Brem MD, Hofman Y, Hendriks RW, Lubberts E (2014) Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol 66(2):340\u2013349","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"8522_CR152","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203(12):2673\u20132682","journal-title":"J Exp Med"},{"issue":"10","key":"8522_CR153","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1073\/pnas.1035999100","volume":"100","author":"S Nakae","year":"2003","unstructured":"Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y (2003) IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 100(10):5986\u20135990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"8522_CR154","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","volume":"2","author":"W Hueber","year":"2010","unstructured":"Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study G et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2(52):52ra72","journal-title":"Sci Transl Med"},{"issue":"10","key":"8522_CR155","first-page":"S1017","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Greenwald MW, Cho CS, Berman A, Jin L, Cameron G, Xie L, Braun D, Banerjee S, Warner L (2011) A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naive to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors. Arthritis Rheum-Us 63(10):S1017\u2013S1017","journal-title":"Arthritis Rheum-Us"},{"issue":"13","key":"8522_CR156","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366(13):1190\u20131199","journal-title":"N Engl J Med"},{"issue":"7","key":"8522_CR157","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","volume":"66","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY et al (2014) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 66(7):1693\u20131704","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"8522_CR158","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH et al (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366(13):1181\u20131189","journal-title":"N Engl J Med"},{"issue":"10","key":"8522_CR159","first-page":"S362","volume":"64","author":"K Pavelka","year":"2012","unstructured":"Pavelka K, Chon Y, Newmark R, Erondu N, Lin SL (2012) A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to Methotrexate. Arthritis Rheum-Us 64(10):S362\u2013S362","journal-title":"Arthritis Rheum-Us"},{"issue":"5","key":"8522_CR160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0301-472X(00)00143-0","volume":"28","author":"A Berer","year":"2000","unstructured":"Berer A, Stockl J, Majdic O, Wagner T, Kollars M, Lechner K, Geissler K, Oehler L (2000) 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 28(5):575\u2013583","journal-title":"Exp Hematol"},{"issue":"10","key":"8522_CR161","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/eji.200838192","volume":"38","author":"L Chen","year":"2008","unstructured":"Chen L, Wei XQ, Evans B, Jiang W, Aeschlimann D (2008) IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 38(10):2845\u20132854","journal-title":"Eur J Immunol"},{"issue":"5","key":"8522_CR162","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/ar2297","volume":"9","author":"T Yago","year":"2007","unstructured":"Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9(5):R96","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"8522_CR163","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4049\/jimmunol.1401013","volume":"194","author":"HS Shin","year":"2015","unstructured":"Shin HS, Sarin R, Dixit N, Wu J, Gershwin E, Bowman EP, Adamopoulos IE (2015) Crosstalk among IL-23 and DNAX activating protein of 12 kDa-dependent pathways promotes osteoclastogenesis. J Immunol 194(1):316\u2013324","journal-title":"J Immunol"},{"issue":"8","key":"8522_CR164","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.4049\/jimmunol.181.8.5720","volume":"181","author":"JM Quinn","year":"2008","unstructured":"Quinn JM, Sims NA, Saleh H, Mirosa D, Thompson K, Bouralexis S, Walker EC, Martin TJ, Gillespie MT (2008) IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol 181(8):5720\u20135729","journal-title":"J Immunol"},{"issue":"5","key":"8522_CR165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00774-007-0766-8","volume":"25","author":"S Kamiya","year":"2007","unstructured":"Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T, Wada S (2007) Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab 25(5):277\u2013285","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"8522_CR166","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4049\/jimmunol.181.2.1507","volume":"181","author":"JH Ju","year":"2008","unstructured":"Ju JH, Cho ML, Moon YM, Oh HJ, Park JS, Jhun JY, Min SY, Cho YG, Park KS, Yoon CH et al (2008) IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 181(2):1507\u20131518","journal-title":"J Immunol"},{"issue":"2","key":"8522_CR167","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.1003986","volume":"187","author":"IE Adamopoulos","year":"2011","unstructured":"Adamopoulos IE, Tessmer M, Chao CC, Adda S, Gorman D, Petro M, Chou CC, Pierce RH, Yao W, Lane NE et al (2011) IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 187(2):951\u2013959","journal-title":"J Immunol"},{"issue":"9","key":"8522_CR168","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14(9):585\u2013600","journal-title":"Nat Rev Immunol"},{"key":"8522_CR169","doi-asserted-by":"crossref","first-page":"53","DOI":"10.22203\/eCM.v015a05","volume":"15","author":"F Shapiro","year":"2008","unstructured":"Shapiro F (2008) Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 15:53\u201376","journal-title":"Eur Cell Mater"},{"issue":"1","key":"8522_CR170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1016-8478(23)17544-3","volume":"25","author":"H Kawaguchi","year":"2008","unstructured":"Kawaguchi H (2008) Endochondral ossification signals in cartilage degradation during osteoarthritis progression in experimental mouse models. Mol Cell 25(1):1\u20136","journal-title":"Mol Cell"},{"issue":"8","key":"8522_CR171","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/term.1918","volume":"9","author":"EM Thompson","year":"2014","unstructured":"Thompson EM, Matsiko A, Farrell E, Kelly DJ, O\u2019Brien FJ (2014) Recapitulating endochondral ossification: a promising route to in vivo bone regeneration. J Tissue Eng Regen Med 9(8):889\u2013902","journal-title":"J Tissue Eng Regen Med"},{"issue":"2","key":"8522_CR172","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/ten.tec.2008.0297","volume":"15","author":"E Farrell","year":"2009","unstructured":"Farrell E, van der Jagt OP, Koevoet W, Kops N, van Manen CJ, Hellingman CA, Jahr H, O\u2019Brien FJ, Verhaar JA, Weinans H et al (2009) Chondrogenic priming of human bone marrow stromal cells: a better route to bone repair? Tissue Eng Part C Methods 15(2):285\u2013295","journal-title":"Tissue Eng Part C Methods"},{"key":"8522_CR173","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2474-12-31","volume":"12","author":"E Farrell","year":"2011","unstructured":"Farrell E, Both SK, Odorfer KI, Koevoet W, Kops N, O\u2019Brien FJ, de Jong RJ B, Verhaar JA, Cuijpers V, Jansen J et al (2011) In-vivo generation of bone via endochondral ossification by in-vitro chondrogenic priming of adult human and rat mesenchymal stem cells. BMC Musculoskelet Disord 12:31","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"8522_CR174","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2106\/JBJS.E.00669","volume":"88","author":"JI Huang","year":"2006","unstructured":"Huang JI, Durbhakula MM, Angele P, Johnstone B, Yoo JU (2006) Lunate arthroplasty with autologous mesenchymal stem cells in a rabbit model. J Bone Joint Surg Am 88(4):744\u2013752","journal-title":"J Bone Joint Surg Am"},{"issue":"8","key":"8522_CR175","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/j.actbio.2010.01.037","volume":"6","author":"P Janicki","year":"2010","unstructured":"Janicki P, Kasten P, Kleinschmidt K, Luginbuehl R, Richter W (2010) Chondrogenic pre-induction of human mesenchymal stem cells on beta-TCP: enhanced bone quality by endochondral heterotopic bone formation. Acta Biomater 6(8):3292\u20133301","journal-title":"Acta Biomater"},{"issue":"19","key":"8522_CR176","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1073\/pnas.0711662105","volume":"105","author":"JM Jukes","year":"2008","unstructured":"Jukes JM, Both SK, Leusink A, Sterk LM, van Blitterswijk CA, de Boer J (2008) Endochondral bone tissue engineering using embryonic stem cells. Proc Natl Acad Sci U S A 105(19):6840\u20136845","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"8522_CR177","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0736-0266(00)00078-4","volume":"19","author":"T Aizawa","year":"2001","unstructured":"Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC (2001) Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res 19(5):785\u2013796","journal-title":"J Orthop Res"},{"issue":"9","key":"8522_CR178","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1359\/jbmr.2003.18.9.1584","volume":"18","author":"LC Gerstenfeld","year":"2003","unstructured":"Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Tsay A, Fitch J, Barnes GL, Graves DT, Einhorn TA (2003) Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 18(9):1584\u20131592","journal-title":"J Bone Miner Res"},{"issue":"11","key":"8522_CR179","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/jbmr.486","volume":"26","author":"R Grimes","year":"2011","unstructured":"Grimes R, Jepsen KJ, Fitch JL, Einhorn TA, Gerstenfeld LC (2011) The transcriptome of fracture healing defines mechanisms of coordination of skeletal and vascular development during endochondral bone formation. J Bone Miner Res 26(11):2597\u20132609","journal-title":"J Bone Miner Res"},{"issue":"10","key":"8522_CR180","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1073\/pnas.1220108110","volume":"110","author":"C Scotti","year":"2013","unstructured":"Scotti C, Piccinini E, Takizawa H, Todorov A, Bourgine P, Papadimitropoulos A, Barbero A, Manz MG, Martin I (2013) Engineering of a functional bone organ through endochondral ossification. Proc Natl Acad Sci U S A 110(10):3997\u20134002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8522_CR181","doi-asserted-by":"crossref","first-page":"224","DOI":"10.22203\/eCM.v024a16","volume":"24","author":"M Mumme","year":"2012","unstructured":"Mumme M, Scotti C, Papadimitropoulos A, Todorov A, Hoffmann W, Bocelli-Tyndall C, Jakob M, Wendt D, Martin I, Barbero A (2012) Interleukin-1beta modulates endochondral ossification by human adult bone marrow stromal cells. Eur Cell Mater 24:224\u2013236","journal-title":"Eur Cell Mater"},{"issue":"10","key":"8522_CR182","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/rheumatology\/keu162","volume":"53","author":"B Hauser","year":"2014","unstructured":"Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH (2014) Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) 53(10):1759\u20131766","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"8522_CR183","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5):1390\u20131400","journal-title":"Arthritis Rheum"},{"issue":"9","key":"8522_CR184","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793\u20132806","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8522_CR185","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","volume":"68","author":"E Keystone","year":"2009","unstructured":"Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK et al (2009) Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68(2):216\u2013221","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8522_CR186","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","volume":"70","author":"PP Tak","year":"2011","unstructured":"Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70(1):39\u201346","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8522_CR187","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2011-200198","volume":"71","author":"MJ Boumans","year":"2012","unstructured":"Boumans MJ, Thurlings RM, Yeo L, Scheel-Toellner D, Vos K, Gerlag DM, Tak PP (2012) Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis 71(1):108\u2013113","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"8522_CR188","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-011-1607-0","volume":"22","author":"G Wheater","year":"2011","unstructured":"Wheater G, Hogan VE, Teng YK, Tekstra J, Lafeber FP, Huizinga TW, Bijlsma JW, Francis RM, Tuck SP, Datta HK et al (2011) Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int 22(12):3067\u20133072","journal-title":"Osteoporos Int"},{"issue":"11","key":"8522_CR189","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/art.24906","volume":"60","author":"RM Fleischmann","year":"2009","unstructured":"Fleischmann RM (2009) Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 60(11):3225\u20133228","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8522_CR190","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/13543784.12.4.673","volume":"12","author":"P Emery","year":"2003","unstructured":"Emery P (2003) The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 12(4):673\u2013681","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"8522_CR191","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaut.2005.09.020","volume":"25","author":"C Kliwinski","year":"2005","unstructured":"Kliwinski C, Kukral D, Postelnek J, Krishnan B, Killar L, Lewin A, Nadler S, Townsend R (2005) Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J Autoimmun 25(3):165\u2013171","journal-title":"J Autoimmun"},{"issue":"11","key":"8522_CR192","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2007.080713","volume":"67","author":"R Axmann","year":"2008","unstructured":"Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67(11):1603\u20131609","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8522_CR193","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353(11):1114\u20131123","journal-title":"N Engl J Med"},{"issue":"12","key":"8522_CR194","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144(12):865\u2013876","journal-title":"Ann Intern Med"},{"issue":"4","key":"8522_CR195","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","volume":"58","author":"JM Kremer","year":"2008","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Teng J, Becker JC et al (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58(4):953\u2013963","journal-title":"Arthritis Rheum"},{"issue":"8","key":"8522_CR196","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/ard.2007.085084","volume":"67","author":"HK Genant","year":"2008","unstructured":"Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, Teng J, Kremer JM (2008) Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 67(8):1084\u20131089","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8522_CR197","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","volume":"12","author":"F Atzeni","year":"2012","unstructured":"Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A et al (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12(2):225\u2013229","journal-title":"Autoimmun Rev"},{"issue":"11","key":"8522_CR198","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.clinthera.2010.10.011","volume":"32","author":"M Khraishi","year":"2010","unstructured":"Khraishi M, Russell A, Olszynski WP (2010) Safety profile of abatacept in rheumatoid arthritis: a review. Clin Ther 32(11):1855\u20131870","journal-title":"Clin Ther"},{"issue":"4","key":"8522_CR199","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.berh.2014.10.017","volume":"28","author":"FM Meier","year":"2014","unstructured":"Meier FM, McInnes IB (2014) Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol 28(4):605\u2013624","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"8522_CR200","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar2365","volume":"10","author":"AJ Milici","year":"2008","unstructured":"Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P (2008) Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 10(1):R14","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"8522_CR201","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","volume":"64","author":"TP LaBranche","year":"2012","unstructured":"LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y et al (2012) JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 64(11):3531\u20133542","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8522_CR202","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"DL Boyle","year":"2015","unstructured":"Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S et al (2015) The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 74(6):1311\u20131316","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"8522_CR203","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","volume":"73","author":"S Kubo","year":"2014","unstructured":"Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y (2014) The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 73(12):2192\u20132198","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8522_CR204","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508\u2013519","journal-title":"N Engl J Med"},{"issue":"9865","key":"8522_CR205","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381(9865):451\u2013460","journal-title":"Lancet"},{"issue":"25","key":"8522_CR206","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370(25):2377\u20132386","journal-title":"N Engl J Med"},{"issue":"4","key":"8522_CR207","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V et al (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64(4):970\u2013981","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8522_CR208","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/ard.2009.108159","volume":"69","author":"JH Coombs","year":"2010","unstructured":"Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH (2010) Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 69(2):413\u2013416","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"8522_CR209","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","volume":"191","author":"L Rompaey Van","year":"2013","unstructured":"Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N et al (2013) Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 191(7):3568\u20133577","journal-title":"J Immunol"},{"issue":"9","key":"8522_CR210","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.4049\/jimmunol.1300514","volume":"192","author":"JS Park","year":"2014","unstructured":"Park JS, Lee J, Lim MA, Kim EK, Kim SM, Ryu JG, Lee JH, Kwok SK, Park KS, Kim HY et al (2014) JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells. J Immunol 192(9):4417\u20134424","journal-title":"J Immunol"},{"issue":"2","key":"8522_CR211","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/ar3329","volume":"13","author":"KL Stump","year":"2011","unstructured":"Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD et al (2011) A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 13(2):R68","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"8522_CR212","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF et al (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184(9):5298\u20135307","journal-title":"J Immunol"},{"issue":"12","key":"8522_CR213","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharmacol 54(12):1354\u20131361","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"8522_CR214","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","volume":"67","author":"RM Fleischmann","year":"2015","unstructured":"Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N (2015) A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheum 67(2):334\u2013343","journal-title":"Arthritis Rheum"},{"issue":"7","key":"8522_CR215","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19(7):1059\u20131066","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8522_CR216","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299\u20131309","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8522_CR217","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/acr.20004","volume":"62","author":"A Deodhar","year":"2010","unstructured":"Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, Ory PA, Peterfy CG, Fuerst T, Wang H et al (2010) Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 62(4):569\u2013574","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"8522_CR218","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.39075","volume":"67","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E (2015) Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol 67(6):1456\u20131464","journal-title":"Arthritis Rheumatol"},{"issue":"5279","key":"8522_CR219","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","volume":"273","author":"BD Gelb","year":"1996","unstructured":"Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273(5279):1236\u20131238","journal-title":"Science"},{"issue":"7","key":"8522_CR220","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00296-007-0506-3","volume":"28","author":"M Skoumal","year":"2008","unstructured":"Skoumal M, Haberhauer G, Kolarz G, Hawa G, Woloszczuk W, Klingler A, Varga F, Klaushofer K (2008) The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. Rheumatol Int 28(7):637\u2013641","journal-title":"Rheumatol Int"},{"key":"8522_CR221","doi-asserted-by":"crossref","first-page":"457876","DOI":"10.1155\/2013\/457876","volume":"2013","author":"EV Tchetina","year":"2013","unstructured":"Tchetina EV, Demidova NV, Karateev DE, Nasonov EL (2013) Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. Int J Rheumatol 2013:457876","journal-title":"Int J Rheumatol"},{"issue":"2","key":"8522_CR222","first-page":"666","volume":"123","author":"S Lotinun","year":"2013","unstructured":"Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E et al (2013) Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 123(2):666\u2013681","journal-title":"J Clin Invest"},{"issue":"2","key":"8522_CR223","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jbmr.223","volume":"26","author":"BL Pennypacker","year":"2011","unstructured":"Pennypacker BL, le Duong T, Cusick TE, Masarachia PJ, Gentile MA, Gauthier JY, Black WC, Scott BB, Samadfam R, Smith SY et al (2011) Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 26(2):252\u2013262","journal-title":"J Bone Miner Res"},{"issue":"2","key":"8522_CR224","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/art.23224","volume":"58","author":"U Schurigt","year":"2008","unstructured":"Schurigt U, Hummel KM, Petrow PK, Gajda M, Stockigt R, Middel P, Zwerina J, Janik T, Bernhardt R, Schuler S et al (2008) Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum 58(2):422\u2013434","journal-title":"Arthritis Rheum"},{"issue":"1-3","key":"8522_CR225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2009.03.074","volume":"613","author":"L Svelander","year":"2009","unstructured":"Svelander L, Erlandsson-Harris H, Astner L, Grabowska U, Klareskog L, Lindstrom E, Hewitt E (2009) Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol 613(1-3):155\u2013162","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"8522_CR226","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","volume":"26","author":"HG Bone","year":"2015","unstructured":"Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC et al (2015) Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int 26(2):699\u2013712","journal-title":"Osteoporos Int"},{"issue":"1","key":"8522_CR227","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jbmr.2292","volume":"30","author":"K Engelke","year":"2015","unstructured":"Engelke K, Fuerst T, Dardzinski B, Kornak J, Ather S, Genant HK, de Papp A (2015) Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial. J Bone Miner Res 30(1):30\u201338","journal-title":"J Bone Miner Res"},{"issue":"2","key":"8522_CR228","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C et al (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26(2):242\u2013251","journal-title":"J Bone Miner Res"},{"key":"8522_CR229","unstructured":"Press release announcing outcome of LOFT trial with odanacatib"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-015-8522-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8522-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:01:11Z","timestamp":1718226071000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-015-8522-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,3]]},"references-count":229,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["8522"],"URL":"https:\/\/doi.org\/10.1007\/s12016-015-8522-7","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,3]]}}}